Life Sciences

Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
September 5, 2012
As the 2012 presidential campaign moves in the final stage, ITIF is presenting general principles and specific recommendations across several policy areas.
August 28, 2012
Negotiations toward the TPP Agreement should conclude with a gold-standard trade agreement.
July 23, 2012
Pharmaceutical proliferation leads to longer, wealthier lives.
July 9, 2012
Based on ITIF’s reports, the unfortunate unemployment in life science and STEM fields has to do with inattention to public policies to keep the U.S. at the cutting edge of innovation.
May 17, 2012
The U.S. needs to re-examine its competitiveness in the life sciences sector.
May 17, 2012
Documents the role public investment plays in underpinning a nation’s competitiveness in the life sciences and competition for global life sciences leadership. NIH Director Francis S. Collins endorses this report in a recent New York Times interview.
November 2, 2011
Join us for an international forum discussing the future of health care innovation in times of financial crisis.
January 12, 2011
Rob Atkinson participated in a panel discussion examining how the U.S. can best foster investment in medical innovation.
November 11, 2010
Rob Atkinson presented at the PILMA Winter Meeting.
July 22, 2010
ITIF presents a conversation with Dr. Rob Epstein, the Chief Medical Officer of Medco to learn more about the latest innovations in healthcare technology.

Pages